Royalty Pharma
RPRX
232 hedge funds and large institutions have $9.59B invested in Royalty Pharma in 2021 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 93 increasing their positions, 78 reducing their positions, and 38 closing their positions.
166% more call options, than puts
Call options by funds: $45.5M | Put options by funds: $17.1M
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
19% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 78
5% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 38
1.6% less ownership
Funds ownership: 63.75% → 62.15% (-1.6%)
2% less funds holding
Funds holding: 236 → 232 (-4)
7% less capital invested
Capital invested by funds: $10.3B → $9.59B (-$674M)
Top Buyers
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
+$511M |
| 2 |
Morgan Stanley
New York
|
+$253M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$221M |
| 4 |
BlackRock
New York
|
+$201M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$84.8M |
Top Sellers
| 1 |
Capital International Investors
Los Angeles,
California
|
-$465M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$194M |
| 3 |
JP Morgan Chase
New York
|
-$77.7M |
| 4 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$56M |
| 5 |
Amundi
Paris,
France
|
-$55.8M |
RPRX Hedge Fund Activity: Q3 2021 in Review
232 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2021, worth a combined $9.59B — down 6.6% from $10.3B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of RPRX and 36 opened new positions — a net loss of 2 holders — while 78 trimmed existing stakes and 93 added.
The largest buyer was Berkshire Hathaway, opening a new position worth an estimated $511M. The largest seller was Capital International Investors, cutting an estimated $465M.
- 232 institutional investors held Royalty Pharma (RPRX) as of Q3 2021, down from 236 in Q2 2021.
- Funds reported $9.59B of Royalty Pharma stock for Q3 2021, down 6.6% quarter-over-quarter.
- 36 funds opened new Royalty Pharma positions in Q3 2021 and 38 closed out, a net change of -2 holders.
- The largest Royalty Pharma buyer in Q3 2021 was Berkshire Hathaway, an estimated $511M added.
- The largest Royalty Pharma seller in Q3 2021 was Capital International Investors, an estimated $465M sold.
Based on aggregated 13F filings for Q3 2021.